Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal.Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA Epigenomic…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
